Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell ...
Rituximab has become the mainstay of systemic therapy for patients with follicular lymphoma and is associated with an improved outcome at both diagnosis and relapse, either as induction or maintenance ...
In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...
Outcome of patients with skeletal involvement was analyzed in a retrospective study of nine consecutive prospective trials of the German High-Grade Non-Hodgkin lymphoma Study Group. Data were ...
SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a ...
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at ...
Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life Two hundred two patients with low–tumor burden FL were randomly assigned to the ...
Phase 3 results from the LyMa trial have shown that rituximab, after autologous stem cell transplant (ASCT), prolongs event-free survival, progression-free survival, and overall survival (OS) in ...
RILD in NHL patients presents as lung disease, organizing pneumonia, and nonspecific interstitial pneumonia, with 179 pathogenic microorganisms identified. The study systematically characterized RILD ...
ImmunityBio launched the ResQ215B Phase 2 trial of a chemotherapy free, outpatient immunotherapy regimen for indolent B cell non Hodgkin lymphoma. The trial combines CAR NK cell therapy with the ...
Rituximab subcutaneous injection (MabThera, Roche Products Limited) was granted a marketing authorisation in March 2014 for treating non-Hodgkin's lymphoma in adults. Rituximab concentrate for ...
Your doctor may talk to you about using immunotherapy to help treat your lymphoma. It’s a newer type of cancer treatment that works with your natural immune system to find and kill cancer cells in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results